BUSULFAN Side Effects

6994544-6 | Arrhythmia Supraventricular, Ascites, Atrial Flutter, Blood Bilirubin Increased, Blood Creatinine Increased, Fluid Retention, Haemothorax, Lung Infiltration
on Sep 15, 2010 Male patient from UNITED STATES , weighting 116.2 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: arrhythmia supraventricular, ascites, atrial flutter, blood bilirubin increased, blood creatinine increased, fluid retention, haemothorax, lung infiltration. Busulfan dosage: 640 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (10000 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (2895 Mg) (View Cyclosporine Review and Cyclosporine Label ), LYMPHOCYTE IMMUNE GLOBULIN (ATGAM; ATG EQUINE) (4500 Mg) (View Lymphocyte Immune Globulin (atgam; Atg Equine) Review and Lymphocyte Immune Globulin (atgam; Atg Equine) Label ), METHOTREXATE (70 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6944600-3 | Ascites, Blood Bilirubin Increased, Blood Creatinine Increased, Fluid Overload, Lung Infiltration, Mucosal Inflammation, Oxygen Consumption Increased, Parainfluenzae Virus Infection, Respiratory Failure
Patient was taking Busulfan (View Usage). Patient had the following side effects: ascites, blood bilirubin increased, blood creatinine increased, fluid overload, lung infiltration, mucosal inflammation, oxygen consumption increased, parainfluenzae virus infection, respiratory failure on Aug 25, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 116.2 lb, . Busulfan dosage: 640 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (10000 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (2895 Mg) (View Cyclosporine Review and Cyclosporine Label ), LYMPHOCYTE IMMUNE GLOBULIN (ATGAM; ATG EQUINE) (4500 Mg) (View Lymphocyte Immune Globulin (atgam; Atg Equine) Review and Lymphocyte Immune Globulin (atgam; Atg Equine) Label ), METHOTREXATE (70 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6905918-3 | Dysphagia, Febrile Neutropenia, Laryngeal Oedema, Mucosal Inflammation, Stridor
Adverse event was reported on Aug 03, 2010 by a Male patient taking Busulfan (View Usage) (Dosage: 1008 Mg) . Location: UNITED STATES , weighting 205.9 lb, After Busulfan was administered, patient had the following side effects: dysphagia, febrile neutropenia, laryngeal oedema, mucosal inflammation, stridor. During the same period patient was treated with CYTARABINE (29140 Mg) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (8560 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (12780 Mg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ). Patient was hospitalized.

6826178-8 | Bacterial Test Positive, Hypoxia, Pleural Effusion, Pulmonary Oedema, Pyrexia, Staphylococcus Test Positive
on Jul 08, 2010 Female patient from UNITED STATES , weighting 203.3 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial test positive, hypoxia, pleural effusion, pulmonary oedema, pyrexia, staphylococcus test positive. Busulfan dosage: 192 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), G CSF (FILGRASTIM, AMGEN) (1800 Mcg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ), METHOTREXATE (24 Mg) (View Methotrexate Review and Methotrexate Label ), TACROLIMUS (100 Mg) (View Tacrolimus Review and Tacrolimus Label ).


6791052-2 | Febrile Neutropenia
on Jun 23, 2010 Male patient from ISRAEL , weighting 147.7 lb, was treated with Busulfan (View Usage). Patient had the following side effects: febrile neutropenia. Busulfan dosage: 974 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (8000 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6776662-0 | Febrile Neutropenia
Patient was taking Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: febrile neutropenia on Jun 17, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 147.7 lb, . Busulfan dosage: 974 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (8000 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6538166-X | Interstitial Lung Disease
Adverse event was reported on Jan 12, 2010 by a Female patient taking Busulfan (View Usage) (Dosage: 800 Mg) . Location: UNITED STATES , weighting 190.9 lb, Patient experienced the following unwanted or unexpected effects: interstitial lung disease. During the same period patient was treated with CYTARABINE (32.8 G) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (6300 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (15060 Mcg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ). Patient was hospitalized.

6414897-7 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Liver
on Oct 26, 2009 Male patient from UNITED STATES , weighting 167.6 lb, was treated with Busulfan (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in liver. Busulfan dosage: 1152 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (8600 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6414033-7 | Acute Graft Versus Host Disease In Liver, Gastrointestinal Disorder
on Oct 22, 2009 Male patient from UNITED STATES , weighting 167.6 lb, was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: acute graft versus host disease in liver, gastrointestinal disorder. Busulfan dosage: 1152 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (8600 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6370422-0 | Chest Pain, Coronary Artery Disease, Electrocardiogram St Segment Elevation, Platelet Count Decreased, Vena Cava Thrombosis
Patient was taking Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), coronary artery disease (What is coronary artery disease?), electrocardiogram st segment elevation, platelet count decreased, vena cava thrombosis on Sep 21, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 197.1 lb, . Busulfan dosage: 848 Mg. During the same period patient was treated with ETOPOSIDE (3978 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (5760 Mg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ). Patient was hospitalized.

6303845-6 | Encephalopathy, Hepatic Failure
Adverse event was reported on Aug 07, 2009 by a Male patient taking Busulfan (View Usage) (Dosage: Mg, Every Day, Iv) was diagnosed with stem cell transplant and. Location: UNITED STATES , 61 years of age, weighting 202.8 lb, Patient had the following side effects: encephalopathy, hepatic failure. During the same period patient was treated with CYCLOPHOSPHAMIDE (4300 Mg, Every Day, Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6229977-9 | Polyomavirus-associated Nephropathy
on Jun 01, 2009 Male patient from UNITED STATES , 50 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: polyomavirus-associated nephropathy. Busulfan dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ALEMTUZUMAB (Total Dose = 60mg) (View Alemtuzumab Review and Alemtuzumab Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized and became disabled.

6207315-5 | Dialysis, Hypoxia, Renal Failure, Respiratory Failure, Transplant Failure, Viraemia
on May 27, 2009 Male patient from UNITED STATES , weighting 165.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: dialysis (What is dialysis?), hypoxia, renal failure, respiratory failure, transplant failure, viraemia. Busulfan dosage: 58 Mg 16 Doses Q 6hr Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (4400 Mg 3 Doses For 3 Days Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6186290-6 | Bone Marrow Transplant, Haematuria, Parotid Gland Enlargement, Proteinuria
Patient was taking Busulfan (View Usage). Patient had the following side effects: bone marrow transplant (What is bone marrow transplant?), haematuria, parotid gland enlargement, proteinuria on May 07, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 152.1 lb, was diagnosed with acute myeloid leukaemia and. Busulfan dosage: 57mg Q 6 Hr To 16 Des Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (3550 Mg 4 Days Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6182377-2 | Cough, Haemorrhage, Mass, Pericardial Effusion
Adverse event was reported on May 05, 2009 by a Female patient taking Busulfan (View Usage) (Dosage: 777.6 Mg) . Location: UNITED STATES , weighting 261.7 lb, After Busulfan was administered, patient had the following side effects: cough, haemorrhage, mass, pericardial effusion. During the same period patient was treated with CYTARABINE (33920 Mg) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (6073 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (15200 Mcg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ). Patient was hospitalized.

6168840-9 | Anxiety, Apnoea, Dialysis, Fluid Overload, Hypoxia, Idiopathic Thrombocytopenic Purpura, Pneumothorax, Renal Failure Acute
on Apr 24, 2009 Male patient from UNITED STATES , weighting 190.7 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: anxiety (What is anxiety?), apnoea, dialysis (What is dialysis?), fluid overload, hypoxia, idiopathic thrombocytopenic purpura, pneumothorax, renal failure acute. Busulfan dosage: 528 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (290 Mg) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ). Patient was hospitalized.

6121468-9 | Acute Respiratory Distress Syndrome, Anaemia Haemolytic Autoimmune, Apnoea, Bk Virus Infection, Blood Culture Positive, Culture Urine Positive, Enterococcal Infection, Fall
on Mar 13, 2009 Male patient from UNITED STATES , weighting 190.7 lb, was treated with Busulfan (View Usage). Patient had the following side effects: acute respiratory distress syndrome, anaemia haemolytic autoimmune, apnoea, bk virus infection, blood culture positive, culture urine positive, enterococcal infection, fall (What is fall?). Busulfan dosage: 528 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (290 Mg) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ). Patient was hospitalized.

6099358-X | Blood Bilirubin Increased, Blood Lactate Dehydrogenase Increased, Haemolysis
Patient was taking Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: blood bilirubin increased, blood lactate dehydrogenase increased, haemolysis on Feb 26, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 201.3 lb, . Busulfan dosage: 528 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (290 Mg) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ). Patient was hospitalized.

6013563-X | Cardiac Arrest, Chest Pain, Cough, Diffuse Alveolar Damage, Dyspnoea, Hypoxia, Lung Disorder, Lung Infiltration, Nasal Flaring
Adverse event was reported on Dec 18, 2008 by a Male patient taking Busulfan (View Usage) (Dosage: 287.2 Mg) . Location: UNITED STATES , weighting 196.2 lb, Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), chest pain (What is chest pain?), cough, diffuse alveolar damage, dyspnoea, hypoxia, lung disorder, lung infiltration, nasal flaring. During the same period patient was treated with CYCLOPHOSPHAMIDE (17960 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6003210-5 | Cardio-respiratory Arrest, Diffuse Alveolar Damage, Lung Infiltration, Pneumothorax, Procedural Complication, Pulmonary Alveolar Haemorrhage
on Dec 15, 2008 Male patient from UNITED STATES , weighting 198.0 lb, was treated with Busulfan (View Usage). Patient had the following side effects: cardio-respiratory arrest, diffuse alveolar damage, lung infiltration, pneumothorax, procedural complication, pulmonary alveolar haemorrhage. Busulfan dosage: 287.2 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (17960 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6000232-5 | Chest Pain, Dyspnoea, Lung Disorder, Lung Infiltration, Nasal Flaring, Oxygen Saturation Decreased, Productive Cough
on Dec 11, 2008 Male patient from UNITED STATES , weighting 198.0 lb, was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: chest pain (What is chest pain?), dyspnoea, lung disorder, lung infiltration, nasal flaring, oxygen saturation decreased, productive cough. Busulfan dosage: 287.2 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (17960 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5977591-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Bilirubin Increased, Chest Discomfort, Continuous Haemodiafiltration, Hepatic Function Abnormal, Hypoxia, Renal Failure Acute
Patient was taking Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, chest discomfort, continuous haemodiafiltration, hepatic function abnormal, hypoxia, renal failure acute on Dec 01, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 157.0 lb, was diagnosed with acute myeloid leukaemia and. Busulfan dosage: 50 Mg 16x Q6hr Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (37200 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

5962663-9 | Alopecia
Adverse event was reported on Jan 23, 2008 by a Male patient taking Busulfan (View Usage) (Dosage: 0.75 Mg/kg;q6h;) . Location: UNITED STATES , 51 years of age, Patient had the following side effects: alopecia. During the same period patient was treated with CYCLOPHOSPHAMIDE (60 Mg/kg;daily;) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (10 Mg/kg;daily;) (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE 0.5MG TAB (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ).

5961336-6 | Alopecia, Post Procedural Complication
on Jan 23, 2008 Female patient from UNITED STATES , 65 years of age, was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: alopecia, post procedural complication. Busulfan dosage: 0.75 Mg/kg;q6h. During the same period patient was treated with CYCLOPHOSPHAMIDE (60 Mg/kg;daily) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (10 Mg/kg;daily) (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

5961331-7 | Alopecia
on Jan 23, 2008 Male patient from UNITED STATES , 55 years of age, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: alopecia. Busulfan dosage: 0.75 Mg/kg;q6h. During the same period patient was treated with CYCLOPHOSPHAMIDE (60 Mg/kg;daily/6000 Mg/m2) (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE 0.5MG TAB (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), ETOPOSIDE (10 Mg/kg;daily) (View Etoposide Review and Etoposide Label ).

5955142-6 | Chest Discomfort, Hypoxia, Tachycardia
Patient was taking Busulfan (View Usage). Patient had the following side effects: chest discomfort, hypoxia, tachycardia on Nov 13, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 157.0 lb, was diagnosed with acute myeloid leukaemia and. Busulfan dosage: 50 Mg 16x Q6hr Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (37200 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5951442-4 | Diarrhoea
Adverse event was reported on Nov 11, 2008 by a Female patient taking Busulfan (View Usage) (Dosage: 50 Mg 16x Q6hr Iv) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , weighting 155.2 lb, After Busulfan was administered, patient had the following side effects: diarrhoea. During the same period patient was treated with CYCLOPHOSPHAMIDE (37200 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5948025-9 | No Therapeutic Response, Pancytopenia, Pyrexia, Transplant Failure
on Nov 10, 2008 Male patient from UNITED STATES , weighting 249.1 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: no therapeutic response, pancytopenia, pyrexia, transplant failure. Busulfan dosage: 148.4 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (928 Mg) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), G CSF (FILGRASTIM, AMGEN) (2.88 Mg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ), METHOTREXATE (44 Mg) (View Methotrexate Review and Methotrexate Label ), TACROLIMUS (220 Mg) (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

5934031-7 | Epistaxis, Thrombocytopenia
on Oct 28, 2008 Female patient from UNITED STATES , weighting 180.8 lb, was diagnosed with acute myeloid leukaemia and was treated with Busulfan (View Usage). Patient had the following side effects: epistaxis, thrombocytopenia. Busulfan dosage: 72 Mg 16x Q6hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (3960 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5921776-8 | Hypoxia, Lobar Pneumonia, Sepsis, Staphylococcal Infection
Patient was taking Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: hypoxia, lobar pneumonia, sepsis (What is sepsis?), staphylococcal infection (What is staphylococcal infection?) on Oct 16, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 219.8 lb, was diagnosed with acute myeloid leukaemia and. Busulfan dosage: 52 Mg 16 Doses /6 Hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (4765 Mg Twice Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5912381-8 | Lobar Pneumonia, Sepsis, Staphylococcal Infection
Adverse event was reported on Oct 07, 2008 by a Female patient taking Busulfan (View Usage) (Dosage: 52 Mg 16 Doses /6 Hr Oral) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , weighting 219.8 lb, Patient experienced the following unwanted or unexpected effects: lobar pneumonia, sepsis (What is sepsis?), staphylococcal infection (What is staphylococcal infection?). During the same period patient was treated with CYCLOPHOSPHAMIDE (4765 Mg Twice Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5859263-8 | Diarrhoea, Graft Versus Host Disease, Nausea, Weight Decreased
on Aug 26, 2008 Female patient from UNITED STATES , weighting 219.8 lb, was diagnosed with acute myeloid leukaemia and was treated with Busulfan (View Usage). Patient had the following side effects: diarrhoea, graft versus host disease, nausea (What is nausea?), weight decreased. Busulfan dosage: 52 Mg 16 Doses /6 Hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (4765 Mg Twice Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5844934-X | Bacteraemia, Haemoptysis, Pneumonia Klebsiella
on Aug 13, 2008 Male patient from UNITED STATES , weighting 155.4 lb, was diagnosed with myelofibrosis and was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: bacteraemia, haemoptysis, pneumonia klebsiella. Busulfan dosage: 66mg 16x Q6hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (4900 Mg 2 Days Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5832346-4 | Ascites, Biliary Tract Disorder, Cytomegalovirus Infection, Diarrhoea, Encephalopathy, Enterococcal Sepsis, Hepatic Enzyme Increased, Hepatic Function Abnormal, Hepatic Vein Thrombosis
Patient was taking Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, biliary tract disorder, cytomegalovirus infection (What is cytomegalovirus infection?), diarrhoea, encephalopathy, enterococcal sepsis, hepatic enzyme increased, hepatic function abnormal, hepatic vein thrombosis on Jul 23, 2008 from UNITED STATES Additional patient health information: Male patient , 25 years of age, was diagnosed with bone marrow transplant (What is bone marrow transplant?) and. Busulfan dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

5830253-4 | Cystitis Haemorrhagic
Adverse event was reported on Jul 25, 2008 by a Male patient taking Busulfan (View Usage) (Dosage: 4mgk Cyclic) was diagnosed with myelodysplastic syndrome and. Location: JAPAN , 56 years of age, Patient had the following side effects: cystitis haemorrhagic. During the same period patient was treated with FLUDARABINE PHOSPHATE (30mgm2 Cyclic) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), TOTAL BODY IRRADIATION (View Total Body Irradiation Review and Total Body Irradiation Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5827104-0 | Abdominal Pain, Clostridium Difficile Toxin Test Positive, Graft Versus Host Disease, Haematemesis
on Jul 29, 2008 Male patient from UNITED STATES , weighting 156.1 lb, was diagnosed with myelofibrosis and was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), clostridium difficile toxin test positive, graft versus host disease, haematemesis. Busulfan dosage: 66mg 16x Q6hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (4900 Mg 2 Days Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5825494-6 | Chest X-ray Abnormal, Dyspnoea, Hypoxia
on Jul 25, 2008 Female patient from UNITED STATES , weighting 129.2 lb, was diagnosed with acute myeloid leukaemia and was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: chest x-ray abnormal, dyspnoea, hypoxia. Busulfan dosage: 56 Mg 16x Q6hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (3600 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

5787678-5 | Encephalitis Viral, Hallucination
Patient was taking Busulfan (View Usage). Patient had the following side effects: encephalitis viral, hallucination on Jun 24, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 129.2 lb, was diagnosed with amyotrophic lateral sclerosis (What is amyotrophic lateral sclerosis?) and. Busulfan dosage: 56 Mg 16 Doses Q 6 Hr Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (3600 Mg Daily X2 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

5637958-9 | Mucosal Inflammation, Pyrexia
Adverse event was reported on Feb 22, 2008 by a Male patient taking Busulfan (View Usage) (Dosage: 1072 Mg) . Location: UNITED STATES , weighting 212.5 lb, After Busulfan was administered, patient had the following side effects: mucosal inflammation, pyrexia. During the same period patient was treated with CYTARABINE (35.2 G) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (8340 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (5400 Mcg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ATIVAN (View Ativan Review and Ativan Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ). Patient was hospitalized.

5630595-1 | Convulsion, Gastrointestinal Haemorrhage, Graft Versus Host Disease, Subarachnoid Haemorrhage
on Feb 15, 2008 Female patient from SLOVAKIA (Slovak Republic) , 52 years of age, weighting 132.3 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, gastrointestinal haemorrhage, graft versus host disease, subarachnoid haemorrhage. Busulfan dosage: 120mg Per Day. During the same period patient was treated with CYCLOPHOSPHAMIDE (4200mg Per Day) (View Cyclophosphamide Review and Cyclophosphamide Label ), ALDESLEUKIN (View Aldesleukin Review and Aldesleukin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), FRAXIPARINE (View Fraxiparine Review and Fraxiparine Label ).

5528069-1 | Ascites, Continuous Haemodiafiltration, Dyspnoea, Gallbladder Enlargement, Haematemesis, Hepatic Failure, Hepatomegaly, Hypopnoea, Multi-organ Failure
on Nov 09, 2007 Female patient from JAPAN , child .7 years of age, was diagnosed with stem cell transplant and was treated with Busulfan (View Usage). Patient had the following side effects: ascites, continuous haemodiafiltration, dyspnoea, gallbladder enlargement, haematemesis, hepatic failure, hepatomegaly, hypopnoea, multi-organ failure. Busulfan dosage: 6.6 Mg;qid;iv.

5526439-9 | Agitation, Anxiety, Confusional State, Mood Altered, Nervous System Disorder
Patient was taking Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: agitation, anxiety (What is anxiety?), confusional state, mood altered, nervous system disorder on Nov 21, 2007 from UNITED STATES Additional patient health information: Male patient , weighting 175.7 lb, was diagnosed with acute myeloid leukaemia and. Busulfan dosage: 78mg Qd. During the same period patient was treated with CYTOXAN (4700 Mg/qd) (View Cytoxan Review and Cytoxan Label ), ATGAM (2350 Mg/ Qd) (View Atgam Review and Atgam Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), DAPSONE (View Dapsone Review and Dapsone Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), ACTIGALL (View Actigall Review and Actigall Label ), NEORAL (View Neoral Review and Neoral Label ), BUDESONIDE (View Budesonide Review and Budesonide Label ). Patient was hospitalized.

5506837-X | Hypovolaemic Shock, Immune System Disorder, Pulmonary Alveolar Haemorrhage, Thrombocytopenia
Adverse event was reported on Oct 24, 2007 by a Male patient taking Busulfan (View Usage) (Dosage: 4 Mg/kg, Day-6 To -5) was diagnosed with prophylaxis against graft versus host disease, antibiotic prophylaxis, antiviral prophylaxis, antifungal prophylaxis and. Location: JAPAN , 60 years of age, Patient experienced the following unwanted or unexpected effects: hypovolaemic shock, immune system disorder, pulmonary alveolar haemorrhage, thrombocytopenia. During the same period patient was treated with TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), FLUDARA (30 Mg/m2, Days -8 To -3) (View Fludara Review and Fludara Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ).

5496979-X | Acute Graft Versus Host Disease, Bone Marrow Transplant, Cholecystitis, Diarrhoea, Hypoalbuminaemia, Oral Intake Reduced, Platelet Count Decreased, Sepsis
on Oct 09, 2007 Male patient from JAPAN , child .8 years of age, was diagnosed with stem cell transplant and was treated with Busulfan (View Usage). Patient had the following side effects: acute graft versus host disease, bone marrow transplant (What is bone marrow transplant?), cholecystitis, diarrhoea, hypoalbuminaemia, oral intake reduced, platelet count decreased, sepsis (What is sepsis?). Busulfan dosage: 0.45 Ml; X1; Iv, 5.08 Ml; X1; Iv. Patient was hospitalized.

5447577-5 | Acute Graft Versus Host Disease, Anorexia, Cytomegalovirus Infection, Diarrhoea, Malaise, Nausea, Sepsis, Stomatitis
on Aug 22, 2007 Male patient from JAPAN , 55 years of age, was diagnosed with stem cell transplant and was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: acute graft versus host disease, anorexia, cytomegalovirus infection (What is cytomegalovirus infection?), diarrhoea, malaise, nausea (What is nausea?), sepsis (What is sepsis?), stomatitis. Busulfan dosage: 32.8 Ml;. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

5447576-3 | Multi-organ Failure, Performance Status Decreased, Venoocclusive Liver Disease
Patient was taking Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: multi-organ failure, performance status decreased, venoocclusive liver disease on Aug 22, 2007 from JAPAN Additional patient health information: Male patient , child 10 years of age, was diagnosed with stem cell transplant and. Busulfan dosage: 0.8 Mg/kg;1x;.

5408208-3 | Clostridium Difficile Colitis, Enterocutaneous Fistula, Febrile Neutropenia, Metabolic Disorder, Sepsis, Stem Cell Transplant
Adverse event was reported on Aug 06, 2007 by a Female patient taking Busulfan (View Usage) (Dosage: 640 Mg) . Location: UNITED STATES , weighting 127.9 lb, Patient had the following side effects: clostridium difficile colitis, enterocutaneous fistula, febrile neutropenia, metabolic disorder (What is metabolic disorder?), sepsis (What is sepsis?), stem cell transplant. During the same period patient was treated with CYTARABINE (26080 Mg) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (7260 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (11510 Mg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ).

5393398-1 | Multi-organ Failure, Septic Shock
on Jul 17, 2007 Male patient from UNITED STATES , weighting 145.5 lb, was treated with Busulfan (View Usage). After Busulfan was administered, patient had the following side effects: multi-organ failure, septic shock. Busulfan dosage: 1024 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (7600 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5392149-4 | Multi-organ Failure, Septic Shock
on Jul 18, 2007 Male patient from UNITED STATES , weighting 145.5 lb, was treated with Busulfan (View Usage). Patient experienced the following unwanted or unexpected effects: multi-organ failure, septic shock. Busulfan dosage: 1024 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (7600 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

5391696-9 | Acute Myeloid Leukaemia, Blood Pressure Decreased, Bone Marrow Transplant Rejection, Cardiac Arrest, Condition Aggravated, Diarrhoea, Respiratory Arrest, Sepsis
Patient was taking Busulfan (View Usage). Patient had the following side effects: acute myeloid leukaemia, blood pressure decreased, bone marrow transplant rejection, cardiac arrest (What is cardiac arrest?), condition aggravated, diarrhoea, respiratory arrest, sepsis (What is sepsis?) on Jul 03, 2007 from JAPAN Additional patient health information: Female patient , 51 years of age, was diagnosed with stem cell transplant and. Busulfan dosage: 26.68 Ml;qd;iv. During the same period patient was treated with VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.